Muscle loss contributes to higher morbidity and mortality in <scp>COPD</scp>: An analysis of national trends

Attaway, Amy; Welch, Nicole; Hatipoğlu, Umur; Zein, Joe; Dasarathy, Srinivasan

doi:10.1111/resp.13877

Cited by 33 publications

(34 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with our results, previous studies have reported a significant effect of sarcopenia on mortality in COPD patients [ 26 – 30 ]. B orda et al .…”

Section: Discussionsupporting

confidence: 93%

Sarcopenia, systemic immune-inflammation index and all-cause mortality in middle-aged and older people with COPD and asthma: a population-based study

et al. 2021

View full text Add to dashboard Cite

BackgroundIncreasing evidence suggests that sarcopenia and a higher systemic immune-inflammation index (SII) are linked with morbidity in patients with chronic obstructive pulmonary disease (COPD). However, whether these two conditions contribute to all-cause mortality in middle-aged and older patients with COPD or asthma is unclear. Therefore, we investigated the association between sarcopenia, SII, COPD, or asthma and all-cause mortality in a large-scale population-based setting.MethodsBetween 2009 and 2014, 4482 participants (aged>55 years, 57.3% female) from the population-based Rotterdam Study were included. COPD and asthma patients were clinically and spirometry-based diagnosed. Six study groups were defined according to the presence or absence of COPD or asthma and sarcopenia. Cox regression models were used to assess all-cause mortality in the study groups, adjusted for sex, age, BMI, SII, smoking, oral corticosteroid use and comorbidities. In addition, all participants were categorised into sex-specific quartiles of SII and mortality in these groups was compared.ResultsOver a median follow-up of 6.1 years (IQR 5.0–7.2), 466 (10.4%) persons died. Independent of the presence of sarcopenia, participants with COPD had a higher risk of all-cause mortality (HR: 2.13 [95% CI: 1.46 to 3.12], and HR: 1.70 [95% CI: 1.32 to 2.18]). Compared to lower SII levels, higher SII levels increased mortality risk even in people without sarcopenia, COPD or asthma.ConclusionMiddle-aged and older people with COPD, higher SII levels or sarcopenia had an independently increased mortality risk. Our study suggests prognostic usefulness of routinely evaluating sarcopenia and SII in older people with COPD or asthma.

show abstract

“…In line with our results, previous studies have reported a significant effect of sarcopenia on mortality in COPD patients [ 26 – 30 ]. B orda et al .…”

Section: Discussionsupporting

confidence: 93%

Sarcopenia, systemic immune-inflammation index and all-cause mortality in middle-aged and older people with COPD and asthma: a population-based study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Finally, muscle weakness is related to an increased utilization of health care resources in patients with COPD [11]. Moreover, Attaway et al recently reported that inhospital mortality, LOS and healthcare costs are higher in patients with COPD exacerbations and low muscle mass [12]. This review addresses the role of acute exacerbations in muscle dysfunction in COPD.…”

Section: Introductionmentioning

confidence: 96%

Role of acute exacerbations in skeletal muscle impairment in COPD

Gosker

Langen

Simons

2020

Expert Review of Respiratory Medicine

View full text Add to dashboard Cite

Introduction: Muscle impairments are prevalent in COPD and have adverse clinical implications in terms of physical performance capacity, disease burden, quality of life and even mortality. During acute exacerbations of COPD (AECOPDs) the respiratory symptoms worsen and this might also apply to the muscle impairments. Areas covered: This report includes a review of both clinical and pre-clinical peer-reviewed literature of the past 20 years found in PubMed providing a comprehensive view on the role of AECOPD in muscle dysfunction in COPD, the putative underlying mechanisms and the treatment perspectives. Expert opinion: The contribution of AECOPD and its recurrent nature to muscle impairment in COPD cannot be ignored and can be attributed to the acutely intensifying and converging disease-related drivers of muscle deterioration, in particular disuse, systemic inflammation and corticosteroid treatment. The search for novel treatment options should focus on the AECOPD-enhanced drivers of muscle dysfunction as well as on the underlying, mainly catabolic, mechanisms. Considering the impact of AECOPD on muscle function, and that of muscle impairment on the recurrence of exacerbations, counteracting muscle deterioration in AECOPD provides an unprecedented therapeutic opportunity.

show abstract

“…Skeletal muscle loss and wasting can be accompanied by a decline in muscle strength, thus increasing risks of falls, fracture, disability, and mortality [ 2 – 4 ]. Furthermore, a low skeletal muscle mass (LMM) has known to be associated with negative outcomes in cardiovascular diseases [ 5 ], stroke [ 6 ], chronic obstructive lung disease [ 7 ], and cancer [ 8 ]. Many studies have reported that aging, physical inactivity, nutritional factor, hormonal changes, and chronic metabolic diseases are risk factors for LMM or sarcopenia [ 9 ].…”

Section: Introductionmentioning

confidence: 99%

Association between Elevated Plasma Homocysteine and Low Skeletal Muscle Mass in Asymptomatic Adults

et al. 2022

View full text Add to dashboard Cite

Background: Homocysteine has been drawing attention with a closed linkage with skeletal muscle. However, the association of hyperhomocysteinemia with decreased skeletal muscle mass remains unclear. We aimed to investigate the association of hyperhomocysteinemia with low skeletal muscle mass (LMM) in asymptomatic adults. Methods: This was a cross-sectional study of 114,583 community-dwelling adults without cancer, stroke, or cardiovascular diseases who underwent measurements of plasma homocysteine and body composition analysis from 2012 to 2018. Hyperhomocysteinemia was defined as >15 µmol/L. Skeletal muscle mass index (SMI) was calculated based on appendicular muscle mass (kg)/height (m) 2 . Participants were classified into three groups based on SMI: "normal," "mildly low," and "severely low." Results: The prevalence of hyperhomocysteinemia was the highest in subjects with severely LMM (12.9%), followed by those with mildly LMM (9.8%), and those with normal muscle mass (8.5%) (P for trend <0.001). In a multivariable logistic regression model, hyperhomocysteinemia was significantly associated with having a mildly LMM (odds ratio [OR], 1.305; 95% confidence interval [CI], 1.224 to 1.392) and severely LMM (OR, 1.958; 95% CI, 1.667 to 2.286), respectively. One unit increment of log-transformed homocysteine was associated with 1.360 and 2.169 times higher risk of having mildly LMM and severely LMM, respectively. Conclusion:We demonstrated that elevated homocysteine has an independent association with LMM in asymptomatic adults, supporting that hyperhomocysteinemia itself can be a risk for decline in skeletal musculature.

show abstract

Muscle loss contributes to higher morbidity and mortality in COPD: An analysis of national trends

Cited by 33 publications

References 65 publications

Sarcopenia, systemic immune-inflammation index and all-cause mortality in middle-aged and older people with COPD and asthma: a population-based study

Sarcopenia, systemic immune-inflammation index and all-cause mortality in middle-aged and older people with COPD and asthma: a population-based study

Role of acute exacerbations in skeletal muscle impairment in COPD

Association between Elevated Plasma Homocysteine and Low Skeletal Muscle Mass in Asymptomatic Adults

Contact Info

Product

Resources

About